Mr. Speaker, I am certainly very grateful to have the opportunity to address the committee of the whole this evening.
I would like to begin with a brief update on the COVID-19 situation in the country, a matter of concern to many Canadians.
As members know, the new COVID-19 variant, omicron, is now circulating in Canada and in many other countries. Early data suggest that omicron may be more transmissible, but evidence is limited at this time. Data are being gathered and shared around the world to determine how this variant affects the severity of illness and vaccine effectiveness.
As a precaution, the Government of Canada rapidly implemented new measures at the border. In addition, the medical, public health and research communities in Canada and elsewhere are actively evaluating omicron, just as they did the previous variants, to understand the potential impact on transmission, clinical presentation and vaccine effectiveness.
Like everyone else, we have to learn to live with the virus and its variants. One recent decision will definitely help us keep up the fight against COVID-19 in Canada. Of course I am talking about Health Canada's authorization of the Pfizer-BioNTech Comirnaty COVID-19 vaccine for use in children aged five to 11.
I am confident the vaccine will help significantly reduce the number of cases in this younger population.
It will protect Canadian children from this virus, and it will also help to further reduce the number of cases nationwide. However, as our chief public health officer, Dr. Tam, said recently, we are not out of the woods yet. We must remain vigilant and continue to meet the challenges of COVID-19 and the new omicron variant.
As the pandemic has evolved, so has our response and the budgetary requirements of the health portfolio. Let me take a moment to provide my hon. colleagues with a financial overview for 2021-22, as outlined in the supplementary estimates (B).
At this time, we are requesting $185.7 million on behalf of the health portfolio, which includes Health Canada, the Public Health Agency of Canada and the Canadian Institutes of Health Research. This increase over the 2021-22 main estimates and supplementary estimates (A) will complement work already under way in a number of important areas.
As always, our focus is on protecting the health and safety of Canadians.
This means that we must ensure that our health care systems are fully prepared to take care of Canadians for the duration of the pandemic.
From day one, the Government of Canada has been there to support the provinces and territories in their fight against COVID-19. More than eight dollars out of every $10 devoted to the fight against COVID-19 were invested by the Canadian government. These investments will help our health care system provide Canadians with the procedures and treatments they need to stay healthy despite the backlog over the past few months.
Health Canada is requesting an extra $181 million to react to the pressures associated with Canada's fight against COVID-19, as well as to address the health care problems that are suffering the consequences of the pandemic.
I would remind hon. members that over the past year, Health Canada has played a key role in the immunization campaign against COVID-19, the biggest campaign in Canada's history. So far, Health Canada has authorized the use of four different COVID-19 vaccines. The Government of Canada has invested more than $9 billion to procure vaccines and treatments, as well as to provide international vaccine aid.
Last week, the National Advisory Committee on Immunization, or NACI, updated its recommendations for the use of booster doses. NACI has made a strong recommendation that the COVID-19 booster dose should be made available to adults over 50 years of age and further recommends that it may be offered to persons 18 to 49 years of age with consideration of individual risks and where they live.
As the Prime Minister said, we have a secure supply of vaccines in Canada and we will receive more early in the new year. The provinces and territories will easily have access to vaccines and booster doses when they are needed.
In the supplementary estimates (B), the Public Health Agency of Canada is transferring $12.4 million to the Canada Border Services Agency for the ongoing development of the ArriveCAN app. This service helps travellers crossing the border comply with COVID-19 public health measures before, while or after crossing the border, for example by storing proof of vaccination.
In addition, the Public Health Agency of Canada is transferring $7 million to the Canadian Institutes of Health Research to expand research that will lead to an understanding of the nature of immunity following COVID-19 infection and vaccination.
Finally, for the Canadian Institutes of Health Research, I am asking for approximately $23.7 million in voted items and $495,000 in statutory credits in the supplementary estimates (B).
These amounts will be used to create the Centre for Research on Pandemic Preparedness and Health Emergencies and to provide training for its highly skilled staff, which will conduct research on pandemics and health emergencies.
The centre's mission is to protect the health of all Canadians by developing and mobilizing research for pandemic and health emergency preparedness, prevention, response and recovery.
In conclusion, I am immensely proud of the careful and coordinated actions of all governments in Canada, which have taken place to protect the health and well-being of Canadians during the COVID-19 pandemic.
I am also proud of how Canadians have responded to public health advice, of the sacrifices they have made and of the resilience they have shown.
As I said earlier, this difficult situation is not over. Canada has confirmed new cases of the omicron variant, and we must continue to monitor the situation closely.
I remind the House that vaccination, in combination with public health measures and personal protective measures, help stop the spread of COVID-19 and its variants in our communities.
My colleague and I would be happy to take questions from members.